Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Alcohol septal ablation in patients with severe septal hypertrophy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Valve regurgitation in patients surviving endocarditis and the subsequent risk of heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Significantly increased risk of all-cause mortality among cardiac patients feeling lonely

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Role of the lymphatic vasculature in cardiovascular medicine

    Research output: Contribution to journalReviewResearchpeer-review

  1. Clinical usefulness of FDG-PET/CT for identification of abnormal extra-cardiac foci in patients with infective endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Salivary microbiota and inflammation-related proteins in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Amyloid transthyretinkardiomyopati

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: The current guidelines suggest alcohol septal ablation (ASA) is less effective in hypertrophic obstructive cardiomyopathy (HOCM) patients with severe left ventricular hypertrophy, despite acknowledging that systematic data are lacking. Therefore, we analysed patients in the Euro-ASA registry to test this statement.

METHODS: We compared the short-term and long-term outcomes of patients with basal interventricular septum (IVS) thickness <30 mm Hg to those with ≥30 mm Hg treated using ASA in nine European centres.

RESULTS: A total of 1519 patients (57±14 years, 49% women) with symptomatic HOCM were treated, including 67 (4.4%) patients with IVS thickness ≥30 mm. The occurrence of short-term major adverse events were similar in both groups. The mean follow-up was 5.4±4.3 years and 5.1±4.1 years, and the all-cause mortality rate was 2.57 and 2.94 deaths per 100 person-years of follow-up in the IVS <30 mm group and the IVS ≥30 mm group (p=0.047), respectively. There were no differences in dyspnoea (New York Heart Association class III/IV 12% vs 16%), residual left ventricular outflow tract gradient (16±20 vs 16±16 mm Hg) and repeated septal reduction procedures (12% vs 18%) in the IVS <30 mm group and IVS ≥30 mm group, respectively (p=NS for all).

CONCLUSIONS: The short-term results and the long-term relief of dyspnoea, residual left ventricular outflow obstruction and occurrence of repeated septal reduction procedures in patients with basal IVS ≥30 mm is similar to those with IVS <30mm. However, long-term all-cause and cardiac mortality rates are worse in the ≥30 mm group.

Original languageEnglish
JournalHeart (British Cardiac Society)
Volume106
Issue number6
Pages (from-to)462-466
Number of pages5
ISSN1355-6037
DOIs
Publication statusPublished - Mar 2020

Bibliographical note

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

    Research areas

  • alcohol septal ablation, hypertrophic cardiomyopathy, outflow gradient, prognosis, survival

ID: 58015341